Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1

Interventions

fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Cyclophosphamide 4Carboplatin 4Topotecan 3Filgrastim 3Etoposide 3Cytarabine 3veliparib 2tipifarnib 2Prednisone 2Imatinib Mesylate 2Decitabine 2Cyclosporine 2Busulfan 2tanespimycin 1sargramostim 1romidepsin 1iadademstat 1decitabine and cedazuridine drug combination 1Vorinostat 1Vitamin E 1Vincristine 1Thiotepa 1Tacrolimus 1Sunitinib 1Specimen Handling 1Rituximab 1Radiotherapy 1Pharmacogenomic Testing 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Polycythemia Vera × iadademstat × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡